Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...

Moderna is down 80% from its 52-week high ... Healthcare conference presentation (slide 11). Combined flu/COVID vaccine: mRNA-1083 The third regulatory catalyst of note would be potential approval ...